Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Anthony @ Equity Investigations, Dear Anthony, -- Ignore unavailable to you. Want to Upgrade?

To: Anthony@Pacific who wrote (56740)	5/20/2000 2:52:00 PM
From: sunshadow	Respond to of 122087

Tony, I do not want my money back... I want you back! Things aren't always as they seem to be as I have learned over the last year. You have a lot of support out here, so heres hoping the time flies very fast. I once said I liked 95% of you and you said that was ok because that was better than your mom's 90%. I do appreciate all that I have learned and hope we can hold the fort down while you are away. With prayer and many thanks!

To: Anthony@Pacific who wrote (56740)	5/21/2000 12:13:00 AM
From: Jon Khymn	Respond to of 122087

Well, Tony, you are one of the last guru to leave SI... Hope you'll have a safe journey, life is such a short journey anyway. I'll pray that next few months will be truly meaningful in your life's journey. During those quiet time, hope you'll find the true meaning of life... and when you find 'em, please come back and share with us. Wish I could have a few months of solitude... May God bless you and keep you, jon

To: Anthony@Pacific who wrote (56740)	5/21/2000 7:11:00 PM
From: unclewest	Respond to of 122087

anthony...here is a going away gift. biz.yahoo.com Sunday May 21, 6:26 pm Eastern Time Imclone drug helps in more cancer cases By Maggie Fox, Health and Science Correspondent NEW ORLEANS, May 21 (Reuters) - A drug that has shown surprising effects against some of the most incurable cancers is continuing to help people who had no hope of treatment, researchers said on Sunday. They said ImClone's experimental drug IMC-225, which had already worked well in a few patients with seemingly incurable head and neck cancer, was also showing promise against colorectal cancer. The drug helps other cancer drugs work better, ImClone researchers told a meeting of the American Society of Clinical Oncology (ASCO) in New Orleans. The company is testing the drug in a number of phase II and III studies but reported interim data at the ASCO meeting. It said 12 patients with head and neck cancer and six patients with colorectal cancer who had not responded to standard chemotherapy showed either a complete remission or a partial response -- which means their tumour shrank by at least 50 percent -- when IMC-225 was added to their chemotherapy. ``We are seeing about a 20 percent response rate in colorectal cancer,'' Dr. Harlan Waksal, M.D., executive vice president and chief operating officer of ImClone Systems, said in an interview. ``The expected response is zero.'' He said he was excited but cautious. ``These are encouraging data but they are early data,'' he said. The company, working with researchers at M.D. Anderson Cancer Centre in Houston, New York Presbyterian Hospital and Florida Cancer Specialists in Bonita Springs, hopes to eventually enroll 125 patients in their trial. All will have cancer that has not responded to the standard chemotherapy treatment. ``What has made people excited about these data is we have only been talking about IMC-225 in squamous cell head and neck cancer,'' Waksal said. Now it is working against a different kind of tumour -- adenocarcinoma. Most cancer drugs are strong poisons that target rapidly dividing cells such as tumour cells. But IMC-225 is a monoclonal antibody -- a genetically engineered protein that recognises specific parts of cells. The first monoclonal antibody to be approved was Genentech's (NYSE:DNA - news) Herceptin, which hit the market in 1998 for breast cancer. In this case the target is the epidermal growth factor receptor (EGFr), which is involved in the growth of tumour cells and their ability to repair the damage done to them by chemotherapy drugs. ``It is blocking the ability of the tumour cell to overcome the DNA damage of chemotherapy,'' Waksal said. Cancer cells are able to turn on genes that can stop mechanisms that are meant to kill them. The drug essentially lets the cells die, the way they are supposed to. ImClone says 90 percent of head and neck cancers over express EGFr, which means they use it to recover from the damage done by chemotherapy. The company estimates that 92 percent of oesophageal cancers, 67 percent of colorectal cancers, 65 percent of prostate and bladder cancers, 60 percent of ovarian and cervical cancers and 50 percent of pancreatic, kidney and lung cancers over express EGFr and thus might respond to IMC-225. The researchers reported on one interesting case in their study -- a woman with lung cancer who had failed several attempts at chemotherapy and who had given up. Unlike other patients, she got IMC-225 alone and while her tumour has not shrunk, it has stopped growing. ``It has now been 40 weeks and she has had stable lung cancer on IMC-225 alone,'' Waksal said. ``She's doing extremely well. Her quality of life has been excellent.'' He said this might suggest that IMC-225 can stabilise cancer on its own.

To: Anthony@Pacific who wrote (56740)	5/22/2000 10:02:00 AM
From: Jim Spitz	Read Replies (2) \| Respond to of 122087

Tony, We will really miss you here. Hang tough and we'll see you in the fall. Warmest regards, jimS

To: Anthony@Pacific who wrote (56740)	5/23/2000 12:10:00 AM
From: 10K a day	Respond to of 122087

We'll Leave the Light on.

To: Anthony@Pacific who wrote (56740)	5/23/2000 8:13:00 PM
From: Wolff	Read Replies (1) \| Respond to of 122087

Tony, Thank You, for all your work and education about the Markets through the sharing of your wealth of your experience. I started reading your posts on Silicon Investor back in October of 1998. And Yes, I was long a stock, and Yes on the big day of the company news, the stock was toasted. I was never pissed off about being on the other side of that trade, but I needed to learn what you saw in the dynamics of that stock. I have been learning, in one-way or the other, along with you since then. Many folks will blame you with their own poor investment choices because their Egos won't let them see their choices as bad, or the Stock as a POS. And you can count on the same folks will be posting that Shorting an OTC:BB is impossible, and Shorting an IPO is illegal. Nevertheless every completed trade will continue to have a Buyer and a Seller...combined. "Security is mostly a superstition, It does not exist in nature Life is either a daring adventure Or nothing" Thanks Bro, for sharing your adventure. Peace on Earth Wolff